Where does Amgen stand with top therapeutic oncology companies?

Quote

anonymous

Guest
1. Genentech
2. BMS
3. Celgene
4. Pfizer
5. Novartis/Merck/Takeda/Abbvie/Bayer/AZ
6. Seattle Genetics
7. Sanofi
8. Amgen


We aren't even a top 5 therapeutic oncology company but #1 in PCP supportive care. Like JNJ is #1 in oncology bandaids or Baxter #1 in oncology IV lines
 








If you are asking because you are considering working here, run. Horrible culture and leadership doesn't have a clue how to handle therapeutic products. They are in business of lawsuits over patents, not the business of developing great therapeutic options for patients.

Be prepared to be babysat and micromanaged. Your job is about checking boxes and not helping your customers or patients.
 












anonymous said:
If this is based off of dollars in sale, take out supportive care products and Amgen has shit.
Click to expand...

Exactly...add up Vectibix, T-Vec, Blin, and Kyprolis and Amgen wouldn't scratch the surface from a revenue standpoint. Heck the highest revenue therapeutic is from Onyx! Amgen is a bastion for primary care hacks who think selling a contract for supportive care products is actually an oncology job. Hence why Amgen has never successfully promoted a therapeutic...that trend continues today.
 




anonymous said:
Exactly...add up Vectibix, T-Vec, Blin, and Kyprolis and Amgen wouldn't scratch the surface from a revenue standpoint. Heck the highest revenue therapeutic is from Onyx! Amgen is a bastion for primary care hacks who think selling a contract for supportive care products is actually an oncology job. Hence why Amgen has never successfully promoted a therapeutic...that trend continues today.
Click to expand...

What's even funnier is Amgen has never developed its own oncology therapeutic.

Tvec - biovex acquisition
Vectibix - abgenix acquisition
Blincyto - micromet acquisition
Kyprolis - onyx acquisition


Not only can Amgen not develop their own oncology drugs, they can't even pick winners when they acquire. It's a combination of dog products and shitty Amgen execution from Inexperienced, cocky leaders.
 




anonymous said:
What's even funnier is Amgen has never developed its own oncology therapeutic.

Tvec - biovex acquisition
Vectibix - abgenix acquisition
Blincyto - micromet acquisition
Kyprolis - onyx acquisition


Not only can Amgen not develop their own oncology drugs, they can't even pick winners when they acquire. It's a combination of dog products and shitty Amgen execution from Inexperienced, cocky leaders.
Click to expand...

Spot on...bad BD, terrible sales and marketing talent makes for a bad 'therapeutic oncology' company. Hence why Amgen OBU is the laughing stock in the market place.
 




anonymous said:
Spot on...bad BD, terrible sales and marketing talent makes for a bad 'therapeutic oncology' company. Hence why Amgen OBU is the laughing stock in the market place.
Click to expand...


Amgen has no therapeutic oncology product that is a cornerstone or franchise building drug. Kyprolis was supposed to be that, but it's MOA limits it to mostly multiple myeloma and it's in a class with velcade going generic in 2 years and with an oral option available. Furthermore, Revlimid and Darzelex will be the foundation of MM treatment, with PI of choice likely to be velcade to keep branded costs down.

Genentech has Avastin, Herceptin, Rituxan.
Pfizer has Ibrance and Sutent
Celgene has Revlimid
Novartis had Gleevec
Abbvie has Imbruvica
BMS has Opdivo, Yervoy
Merck has Keytruda

Amgen's therapeutic oncology drugs if they were NFL players would be your 2nd or 3rd string backup. The companies above have franchise starters.
 








Top Bottom
Back
Quote